GDF15 and heart failure: A phase 2 randomized clinical trial is currently assessing the effect of ponsegromab (a monoclonal anti-GDF15 neutralizing antibody) on frequency, severity, and burden of symptoms as well as physical limitations in participants with heart failure and elevated circulating GDF-15 concentrations (NCT05492500).